Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
Metrics to compare | RVV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVVPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −0.3x | −0.5x | |
PEG Ratio | −0.11 | 0.00 | 0.00 | |
Price/Book | 1.8x | 0.7x | 2.6x | |
Price / LTM Sales | - | 0.7x | 3.0x | |
Upside (Analyst Target) | - | 92.5% | 52.6% | |
Fair Value Upside | Unlock | 4.8% | 8.8% | Unlock |